Mixed Trial Results Might Change The Case For Investing In Bristol Myers Squibb (BMY)
- Bristol Myers Squibb reported Phase 3 topline data showing RYZ101 improved progression free survival in GEP NETs, and that a lower dose of admilparant met the primary lung function endpoint in idiopathic pulmonary fibrosis, while the higher dose did not reach statistical significance.
- The mix of strong cancer results and uneven efficacy signals in pulmonary fibrosis highlights how Bristol Myers Squibb’s late stage pipeline can both support potential future franchises and introduce additional execution risk around dose selection and trial design.
- We examine how Bristol Myers Squibb’s investment narrative is tested by admilparant’s mixed Phase 3 dose response in idiopathic pulmonary fibrosis.
Bristol-Myers Squibb Investment Narrative Recap
To own Bristol Myers Squibb, you need to be comfortable with a story where the legacy blockbusters face patent pressure while the growth portfolio and late stage pipeline work to fill the gap. The ACTION 1 and EXCALIBER RRMM wins fit that script. The mixed ALOFT IPF dose response for admilparant complicates it, but does not look like a thesis breaker on its own.
In the near term, the key swing factor is still whether new oncology, cardiovascular and immunology launches can keep cash flow healthy as Eliquis moves toward its 2028 patent cliff. The biggest risk is that late stage programs like admilparant or milvexian underperform or slip, which could leave earnings and margins under pressure as older franchises mature.
The most relevant fresh data point here is the ACTION 1 readout for RYZ101 in GEP NETs. That program now joins ZENBEXUS in multiple myeloma and newer assets like Camzyos as part of Bristol Myers Squibb’s attempt to shift more of its revenue base toward recently launched or still developing therapies while legacy products face competition.
For you as an investor, RYZ101’s progress matters because it shows the RayzeBio acquisition feeding into the oncology engine at the same time as admilparant introduces some execution questions in fibrosis. Upcoming regulatory discussions and fuller data for both drugs will help clarify whether the growth portfolio is deep enough and soon enough to offset patent cliffs and pricing pressure.
Bristol-Myers Squibb’s current analyst narrative points to revenues of US$40.1b and earnings of US$8.3b by 2029, based on forecasts that the top line will decline about 6.6% per year and profit margins will lift from 18.9% to 20.6%. That outlook implies a move from US$9.3b in earnings today to the 2029 consensus, which is a decrease of about US$1b. It asks investors to weigh whether a higher future P/E of 20.6x on those earnings is reasonable compared with both the present 13.8x multiple and the wider US pharmaceuticals sector.
Uncover how Bristol-Myers Squibb's fair value indicates a 13% potential upside to its current price before the market closes the discount.
Exploring Other Perspectives
Some bullish analysts frame Bristol Myers Squibb very differently. You have forecasts that look for about US$42.8b of revenue and US$10.6b of earnings by 2029, versus the US$40.1b and US$8.3b baseline, because they treat Eliquis erosion as more manageable. The fresh RYZ101 and admilparant data could easily shift both sets of views, so it is worth exploring both perspectives.
Explore 3 other Bristol-Myers Squibb fair value estimates, including one that suggests as much as 101% upside from the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research and analysis.
- A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Bristol-Myers Squibb. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.
Looking for more Bristol-Myers Squibb sized ideas?
If this Bristol-Myers Squibb update has sharpened your view on risk, reward and pipeline uncertainty, it can help to line it up against other opportunities that fit different profiles. The Simply Wall St Screener lets you filter for financial strength, valuation and income, so you can build a watchlist that matches the kind of journey you want your capital to take.
- If you want resilient balance sheets and cleaner fundamentals, start with a list of solid balance sheet and fundamentals (25 results) that prioritises financial strength instead of story.
- For investors hunting for mispriced businesses, compare this situation with a 32 high quality undervalued stocks that screens for quality and valuation in one place.
- If steady income is the anchor of your plan, set Bristol-Myers Squibb alongside a 7 dividend fortresses that focuses on higher yielding payers with robust profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com